Omeros' Ophthalmology Product OMS302 Successful in Second Phase 3 Clinical Trial
people are talking about how much money is on hand. Ive been in this one for a long time and anytime you see a GPCR announcment (positive) you can count on an afterhours kick in the pants. 30 mil burn 10 on hand..... anyone guess whats next?
scubamoe, regarding funds on hand, don't forget the following from the last Q:
"On July 2, 2012, we completed a public offering pursuant to which we sold 3,365,854 shares of our common stock at a price of $10.25 per share. After
deducting underwriting discounts and other estimated offering expenses payable by us, our estimated net proceeds from the transaction were $32.4 million.
We believe that our existing cash, cash equivalents and short-term investments and available capital under our committed equity line financing facility will be
sufficient to fund our anticipated operating expenses, capital expenditures and note payments for at least the next 12 months. Our assumptions include our
ability to raise capital under our $40.0 million equity line financing facility with Azimuth."